A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Trial Category:
Hematologic
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Hematology Oncology, Lincoln, NE

This study is looking at new drugs to help with patients diagnosed with Multiple Myeloma who have relapsed (showing signs of active cancer) or who are refractory (resistant to treatment).

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members